SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19 – A Review
The relationship between SARS-CoV-2 dose, infection, and COVID-19 outcomes remains poorly understood. This review summarizes the existing literature regarding this issue, identifies gaps in current knowledge, and suggests opportunities for future research.
Effectiveness of BNT162b2 mRNA COVID-19 vaccine against acquisitions of SARS-CoV-2 among health care workers in long-term care facilities: a prospective cohort study
We assessed vaccine effectiveness (VE) of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 acquisition among health care workers (HCWs) of long-term care facilities (LTCFs).
Secondary Cases of Delta-Variant COVID-19 Among Vaccinated Healthcare Workers with Breakthrough Infections is Rare
A retrospective cohort study at four academic medical centers with high COVID-19 vaccination rates evaluated breakthrough SARS-CoV-2 Delta variant (B.1.617.2) infections in vaccinated healthcare workers. Few work-related secondary cases were identified. Breakthrough cases were largely due to unmasked social activities outside of work.
mRNA Vaccine-Elicited SARS-CoV-2-Specific T cells Persist at 6 Months and Recognize the Delta Variant
Little is known about the decay kinetics of COVID-19 vaccine-elicited SARS-CoV-2 specific T cells. In this study we show a modest decline in the frequency of these T cells at 6 months and demonstrate robust expansion in response to antigen and recognition of spike peptides from the delta variant.
Clinical and Genomic Characterization of SARS CoV-2 infections in mRNA Vaccinated Health Care Personnel in New York City
Vaccine-induced clinical protection against SARS CoV-2 variants is an evolving target. There is limited genomic level data on SARS CoV-2 breakthrough infections and vaccine effectiveness (VE) since the global spread of the B.1.617.2 (Delta) variant.
Severity, criticality, and fatality of the SARS-CoV-2 Beta variant
Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher.
The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009–2019
Hepatitis C virus (HCV) infection has been reported among gay, bisexual, and other men who have sex with men (GBM) globally including GBM with human immunodeficiency virus (HIV) and HIV-negative GBM, particularly those using HIV preexposure prophylaxis (PrEP).
Safety and efficacy of levamisole in loiasis: a randomized, placebo-controlled, double-blind clinical trial
Individuals with high microfilarial densities (MFD) of Loa loa are at risk of developing serious adverse events (SAEs) after ivermectin treatment. Pretreatment with drugs progressively reducing Loa MFD below the risk threshold might help prevent these SAEs. We assessed the safety and efficacy of levamisole for this purpose.
Resistance in Enterobacterales is higher among people with HIV
Multidrug-resistant Enterobacterales (MDR-E) are important pathogens. People with human immunodeficiency virus (HIV) may be at greater risk for MDR-E infection given relatively high antibiotic exposure and burden of comorbidities.
Clinical Infectious Diseases Curated Content
CID has published a variety of critical papers, keen insights and useful recommendations in 2021. Investigate our curated content collections for the month of October:
COVID Transmission
HIV/AIDS
Vector-Borne Diseases
Read curated content
Society Members
For your free access to this journal, log in via the IDSA members area.
Register to receive email alerts, and keep up to date with the latest Clinical Infectious Diseases articles as soon as they are published online. And, with the IDSA Journals app, it's easy to stay connected, giving you the freedom to read the journal both online and offline, on your iPad, iPhone, or iPod Touch.
Sign up for alerts
